Moreover, although there is limited evidence to suggest a direct association between SGLT2 inhibitor use and arrhythmia risk, some studies have revealed a potential protective effect of these medications against atrial fibrillation and ventricular arrhythmias 53-55. Here, SLC5A2 is linked to atrial fibrillation.